The Value of Placental Vascularization and Placental Volume in Pregnancy in APLS

• Conditions: Antiphospholipid Syndrome in Pregnancy

• Registration Number: NCT03505840
• Lead Sponsor: Aljazeera Hospital

Brief Summary

Antiphospholipid antibodies are autoantibodies directed against phospholipid-binding proteins. Among these groups of antibodies, lupus anticoagulant (LA) and anticardiolipin antibodies (aCL)

Detailed Description

APLS can be primary when no evidence of autoimmune disease is found, or secondary to autoimmune processes like systemic lupus erythematous (SLE) in a 40% of the cases.

Study Timeline

• Study First Submitted: 2018-04-13
• Study First Submitted QC: 2018-04-20
• Study First Posted: 2018-04-23
• Study Start: 2018-04-24
• Status Verified: 2020-01
• Last Update Submitted: 2020-01-24
• Last Update Posted: 2020-01-27
• Primary Completion: 2020-09-04
• Study Completion: 2020-10-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 100

Inclusion Criteria

• Singleton pregnancy.

  • Gestational age of 34-37 weeks.
  • Pregnant women with antiphospholipid syndrome

Exclusion Criteria

• Twin or multiple pregnancies.
• Congenital fetal anomalies.
• Gestational age of less than 34.
• Gestational age of more than 37.
• Women with placental or umbilical artery anomalies.
• Antepartum hemorrhage (placental abruption, placenta previa and vasa previa).
• Posterior placenta.
• History of rupture of membrane.
• Patient refusal or fall outs.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The number of participants who will have impaired placental doppler indices	within 2 months

Trial Locations

Locations (1)

Algazeerah; 🇪🇬 Giza, Egypt